BCAL Diagnostics

BCAL Diagnostics Goodwill/Assets

Goodwill to Total Assets Ratio of BCAL Diagnostics (BDX.AX) as of Oct 17, 2026.

Goodwill/Assets

0.00

Last updated:

Goodwill to Total Assets Ratio of BCAL Diagnostics is 2025 0.00 . Goodwill to Total Assets Ratio of BCAL Diagnostics was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BCAL Diagnostics Stock analysis

What does BCAL Diagnostics do? BCAL Diagnostics Ltd, based in Sydney, Australia, operates in the Health Care sector within the Biotechnology industry. The company develops innovative blood screening tests for early breast cancer detection, focusing on a lipid biomarker-based approach known as the BCAL test. This technology complements existing imaging methods like mammograms and aims to support screening and monitoring for women of all ages and backgrounds. BCAL Diagnostics has partnered with Precion Inc. to advance clinical trials and regulatory approvals for its diagnostic solutions. BCAL Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BCAL Diagnostics stock

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio BCAL Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's BCAL Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BCAL Diagnostics

All Key Metrics — BCAL Diagnostics